2023 Breakfast Briefings
June 8th, 2023 

Supported through an independent educational grant from Merck.

Abstract Info

Updated Analysis of Bellwave-001: A Phase ½ Open-Label Dose-Expansion Study of the Efficacy and Safety of Nemtabrutinib for the Treatment of B-Cell Malignancies

Number: p628

Author: Farrukh Awan

Abstract (pdf)

Moderator

Moderator-Ghia

Paolo Ghia, MD, PhD

Full Professor, Medical Oncology

Director, Strategic Research Program on CLL

Deputy Chairman, Experimental Oncology Division Head, B-Cell

Neoplasia Unit

Università Vita-Salute San Raffaele

RCCS Ospedale San Raffaele

Milano, Italy